Skip to content

Ultragenyx Pharmaceutical RARE Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$8.8M-291%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-$294K
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-$27K-640%
Amgen logo
AmgenAMGN
Moderna logo
ModernaMRNA
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.83B-39.4%
P/S4.2×-3.7×

Profitability

See full
Gross margin97.2%
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's other noncash income (expense)?
Ultragenyx Pharmaceutical (RARE) reported other noncash income (expense) of -$1M in Q1 2026.
How has Ultragenyx Pharmaceutical's other noncash income (expense) changed year-over-year?
Ultragenyx Pharmaceutical's other noncash income (expense) decreased by 200.0% year-over-year, from $1M to -$1M.
What does other noncash income (expense) mean?
This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.